Study Title:
A Randomized; Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968]; Crizotinib [NSC #749005]; Savolitinib [NSC #785348]; and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
Lead Group:
Status:
Review Status: